Effect of desferrioxamine on urinary copper and zinc excretion in β-thalassemia major patients

Nejat Akar, Mustafa Tekin, Zümrüt Uysal, Ömer Uzunali

Research output: Contribution to journalArticle

Abstract

Twenty-one β-thalassemia major patients were included to study urinary zinc and copper excretion before and after high dose desfenioxamine (DF). The mean basal zinc excretion (1193.72 ± 1079.64 μg/24 hr) was higher than the mean zinc excretion observed in controls (427.6 ± 74.37 μg/24 hr) (P < 0.001). There was no significant difference between urinary copper levels of patients (185.48 ± 175.45 μg/dl) and the control group (150.0 ± 37 μg/dl) (P > 0.05). No significant difference was observed between the mean basal zinc levels and zinc levels after treatment (1751.06 ± 1462.72 μg/24 hr) (P > 0.05). Although the mean copper excretion was decreased following DF treatment (164.16 ± 117.8 μg/dl), the difference was not significant (P > 0.1). There was a significant interaction for urinary copper and zinc excretion (r = 0.413; P < 0.05). (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)195-198
Number of pages4
JournalJournal of Trace Elements in Experimental Medicine
Volume13
Issue number2
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Deferoxamine
beta-Thalassemia
Zinc
Copper
Therapeutics

Keywords

  • Copper
  • Thalassemia
  • Zinc

ASJC Scopus subject areas

  • Biochemistry

Cite this

Effect of desferrioxamine on urinary copper and zinc excretion in β-thalassemia major patients. / Akar, Nejat; Tekin, Mustafa; Uysal, Zümrüt; Uzunali, Ömer.

In: Journal of Trace Elements in Experimental Medicine, Vol. 13, No. 2, 01.01.2000, p. 195-198.

Research output: Contribution to journalArticle

@article{15338818f9b843398f55f93e8d757b4c,
title = "Effect of desferrioxamine on urinary copper and zinc excretion in β-thalassemia major patients",
abstract = "Twenty-one β-thalassemia major patients were included to study urinary zinc and copper excretion before and after high dose desfenioxamine (DF). The mean basal zinc excretion (1193.72 ± 1079.64 μg/24 hr) was higher than the mean zinc excretion observed in controls (427.6 ± 74.37 μg/24 hr) (P < 0.001). There was no significant difference between urinary copper levels of patients (185.48 ± 175.45 μg/dl) and the control group (150.0 ± 37 μg/dl) (P > 0.05). No significant difference was observed between the mean basal zinc levels and zinc levels after treatment (1751.06 ± 1462.72 μg/24 hr) (P > 0.05). Although the mean copper excretion was decreased following DF treatment (164.16 ± 117.8 μg/dl), the difference was not significant (P > 0.1). There was a significant interaction for urinary copper and zinc excretion (r = 0.413; P < 0.05). (C) 2000 Wiley-Liss, Inc.",
keywords = "Copper, Thalassemia, Zinc",
author = "Nejat Akar and Mustafa Tekin and Z{\"u}mr{\"u}t Uysal and {\"O}mer Uzunali",
year = "2000",
month = "1",
day = "1",
doi = "10.1002/(SICI)1520-670X(2000)13:2<195::AID-JTRA2>3.0.CO;2-9",
language = "English",
volume = "13",
pages = "195--198",
journal = "Journal of Trace Elements in Experimental Medicine",
issn = "0896-548X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of desferrioxamine on urinary copper and zinc excretion in β-thalassemia major patients

AU - Akar, Nejat

AU - Tekin, Mustafa

AU - Uysal, Zümrüt

AU - Uzunali, Ömer

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Twenty-one β-thalassemia major patients were included to study urinary zinc and copper excretion before and after high dose desfenioxamine (DF). The mean basal zinc excretion (1193.72 ± 1079.64 μg/24 hr) was higher than the mean zinc excretion observed in controls (427.6 ± 74.37 μg/24 hr) (P < 0.001). There was no significant difference between urinary copper levels of patients (185.48 ± 175.45 μg/dl) and the control group (150.0 ± 37 μg/dl) (P > 0.05). No significant difference was observed between the mean basal zinc levels and zinc levels after treatment (1751.06 ± 1462.72 μg/24 hr) (P > 0.05). Although the mean copper excretion was decreased following DF treatment (164.16 ± 117.8 μg/dl), the difference was not significant (P > 0.1). There was a significant interaction for urinary copper and zinc excretion (r = 0.413; P < 0.05). (C) 2000 Wiley-Liss, Inc.

AB - Twenty-one β-thalassemia major patients were included to study urinary zinc and copper excretion before and after high dose desfenioxamine (DF). The mean basal zinc excretion (1193.72 ± 1079.64 μg/24 hr) was higher than the mean zinc excretion observed in controls (427.6 ± 74.37 μg/24 hr) (P < 0.001). There was no significant difference between urinary copper levels of patients (185.48 ± 175.45 μg/dl) and the control group (150.0 ± 37 μg/dl) (P > 0.05). No significant difference was observed between the mean basal zinc levels and zinc levels after treatment (1751.06 ± 1462.72 μg/24 hr) (P > 0.05). Although the mean copper excretion was decreased following DF treatment (164.16 ± 117.8 μg/dl), the difference was not significant (P > 0.1). There was a significant interaction for urinary copper and zinc excretion (r = 0.413; P < 0.05). (C) 2000 Wiley-Liss, Inc.

KW - Copper

KW - Thalassemia

KW - Zinc

UR - http://www.scopus.com/inward/record.url?scp=0034052310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034052310&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-670X(2000)13:2<195::AID-JTRA2>3.0.CO;2-9

DO - 10.1002/(SICI)1520-670X(2000)13:2<195::AID-JTRA2>3.0.CO;2-9

M3 - Article

VL - 13

SP - 195

EP - 198

JO - Journal of Trace Elements in Experimental Medicine

JF - Journal of Trace Elements in Experimental Medicine

SN - 0896-548X

IS - 2

ER -